COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S (OMX:BAVA) announced today that it has entered a new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS® smallpox/monkeypox vaccine. Deliveries and all revenues under this contract will occur in 2023 and thus the order has no impact on the financial guidance for this year.
Read more at globenewswire.comBavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here